美国住院输卵管结扎与长效可逆避孕发生率更新
基于2016至2018年美国全国住院患者样本数据库(20%社区医院出院样本),分析分娩住院期间宫内节育器置入、避孕植入物置入及输卵管结扎的发生率及预测因素。结果显示宫内节育器置入率从2016年2.2/1000分娩升至2018年约5.0/1000分娩,植入物置入率从0.3/1000升至2.5/1000,输卵管结扎从64.2/1000降至62.1/1000。剖宫产者输卵管结扎的校正比值比高于阴道分娩者。
要点
- 2016至2018年宫内节育器置入率从2.2/1000分娩升至约5.0/1000分娩(P<.0001)。
- 避孕植入物置入率从0.3/1000分娩升至2.5/1000分娩(P<.0001),输卵管结扎从64.2降至62.1/1000分娩(P<.0001)。
- 剖宫产者行输卵管结扎的校正比值比为8.83(95%CI 8.73-8.97),高于阴道分娩者。
核心结论
- 长效可逆避孕置入率持续上升,而住院产后输卵管结扎率缓慢下降,患者特征差异与接受长效可逆避孕或输卵管结扎相关。
研究设计与样本
- 使用2016至2018年美国全国住院患者样本数据库(覆盖美国所有社区医院出院病例的20%)识别分娩住院期间同时行宫内节育器置入、避孕植入物置入或输卵管结扎的病例。
- 样本包括2,216,638例出院记录,代表全美11,083,180例分娩住院的20%。
- 采用加权多因素logistic回归分析年龄、分娩方式、支付方、地理区域和年份与长效可逆避孕及输卵管结扎 odds 的关联。
主要发现
- 宫内节育器置入率从2016年2.2/1000分娩增至2018年约5.0/1000分娩(P<.0001)。
- 避孕植入物置入率从2016年0.3/1000分娩增至2018年2.5/1000分娩(P<.0001)。
- 输卵管结扎率从64.2/1000分娩降至62.1/1000分娩(P<.0001)。
- 剖宫产者行输卵管结扎的校正比值比为8.83(95%CI 8.73-8.97),高于阴道分娩者。
- 年龄<25岁者接受长效可逆避孕相对于输卵管结扎的校正比值比为7.38(95%CI 6.90-7.90);公共保险者相对于商业保险者接受长效可逆避孕的校正比值比为4.83(95%CI 4.59-5.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inpatient insertion of long-acting reversible contraception and immediate postpartum tubal ligation allow women to initiate highly effective contraception before hospital discharge. OBJECTIVE: We measured rates of intrauterine device and contraceptive implant initiation and tubal ligations performed during delivery hospitalizations from 2016 to 2018 from a representative sample of US hospital discharges. STUDY DESIGN: We used the 2016 to 2018 National Inpatient Sample database, a 20% sample of all community hospital discharges in the United States, to identify delivery hospitalizations with concomitant intrauterine device insertion, contraceptive implant insertion, or tubal ligation. We performed weighted multivariable logistic regression to examine associations between possible predictors (age, delivery mode, payer, geographic region, and year) and odds of long-acting reversible contraception and tubal ligation, and to compare characteristics of users. RESULTS: This sample included 2,216,638 discharges, representing 20% of 11,083,180 delivery hospitalizations across the United States. Intrauterine device insertion increased from 2.2 per 1000 deliveries (2016) to approximately 5.0 per 1000 deliveries (2018; P<.0001); implant insertion increased from 0.3 per 1000 deliveries (2016) to 2.5 per 1000 deliveries (2018; P<.0001); tubal ligation procedures decreased (64.2 to 62.1 per 1000 deliveries; P<.0001). Women who underwent a cesarean delivery had higher odds of having a tubal ligation than those who had a vaginal delivery (adjusted odds ratio, 8.83; 95% confidence interval, 8.73-8.97). Women aged <25 years had 7 times higher odds of receiving long-acting reversible contraception than of receiving tubal ligation (adjusted odds ratio, 7.38; 95% confidence interval, 6.90-7.90). Women with public insurance had almost 5 times the odds of receiving long-acting reversible contraception compared with those with commercial insurance (adjusted odds ratio, 4.83; 95% confidence interval, 4.59-5.06). CONCLUSION: Rates of long-acting reversible contraception insertion continue to increase while the rates of inpatient postpartum tubal ligations slowly decline. Variations in patient characteristics are associated with receiving long-acting reversible contraception or tubal ligation.
引用
- Fang NZ, Westhoff CL. Update on incidence of inpatient tubal ligation and long-acting reversible contraception in the United States. Am J Obstet Gynecol. 2022. PMID: 35569515. doi:10.1016/j.ajog.2022.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。